| Drug General Information |
| Drug ID |
D03AKL
|
| Former ID |
DIB007188
|
| Drug Name |
ATLIPROFEN METHYL ESTER
|
| Synonyms |
IDPH-8261; Atliprofen methyl ester < Prop INNM >; 2-[4-(3-Thienyl)phenyl]propionic acid methyl ester
|
| Drug Type |
Small molecular drug
|
| Indication |
Inflammation [ICD10:E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89]
|
Terminated |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C14H14O2S
|
| Canonical SMILES |
CC(C1=CC=C(C=C1)C2=CSC=C2)C(=O)OC
|
| InChI |
1S/C14H14O2S/c1-10(14(15)16-2)11-3-5-12(6-4-11)13-7-8-17-9-13/h3-10H,1-2H3
|
| InChIKey |
WINXAKJYORVNHU-UHFFFAOYSA-N
|
| CAS Number |
CAS 108912-17-0
|
| PubChem Compound ID |
|
| PubChem Substance ID |
10242769, 12014055, 15246302, 29309459, 50025834, 50639668, 57343622, 104374056, 129586742, 135086270, 137038598, 160676665, 176229972, 179322381, 215781616, 230945588
|
| Target and Pathway |
| Target(s) |
Prostaglandin G/H synthase 1 |
Target Info |
Modulator |
[2]
|
|---|
| Prostaglandin G/H synthase 2 |
Target Info |
Modulator |
[2]
|
|
BioCyc Pathway
|
C20 prostanoid biosynthesisPWY66-393:Aspirin-triggered lipoxin biosynthesis
|
|
Aspirin triggered resolvin D biosynthesis
|
|
C20 prostanoid biosynthesis
|
|
Aspirin triggered resolvin E biosynthesis
|
|
KEGG Pathway
|
Arachidonic acid metabolism
|
|
Metabolic pathways
|
|
Platelet activation
|
|
Serotonergic synapsehsa00590:Arachidonic acid metabolism
|
|
NF-kappa B signaling pathway
|
|
VEGF signaling pathway
|
|
TNF signaling pathway
|
|
Retrograde endocannabinoid signaling
|
|
Serotonergic synapse
|
|
Ovarian steroidogenesis
|
|
Oxytocin signaling pathway
|
|
Regulation of lipolysis in adipocytes
|
|
Leishmaniasis
|
|
Pathways in cancer
|
|
Chemical carcinogenesis
|
|
MicroRNAs in cancer
|
|
Small cell lung cancer
|
|
NetPath Pathway
|
TGF_beta_Receptor Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
|
TSH Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
IL5 Signaling Pathway
|
|
PANTHER Pathway
|
Inflammation mediated by chemokine and cytokine signaling pathwayP00019:Endothelin signaling pathway
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Toll receptor signaling pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
S1P1 pathway
|
|
C-MYB transcription factor network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
Calcium signaling in the CD4+ TCR pathway
|
|
PathWhiz Pathway
|
Arachidonic Acid MetabolismPW000044:Arachidonic Acid Metabolism
|
|
WikiPathways
|
Prostaglandin Synthesis and Regulation
|
|
Arachidonic acid metabolism
|
|
Phase 1 - Functionalization of compounds
|
|
Eicosanoid Synthesis
|
|
Selenium Micronutrient NetworkWP98:Prostaglandin Synthesis and Regulation
|
|
Aryl Hydrocarbon Receptor
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Selenium Micronutrient Network
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000964) |
|---|
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. |
|---|
